首页> 外文期刊>Anesthesia and Analgesia: Journal of the International Anesthesia Research Society >Long-acting local anesthetics attenuate FMLP-induced acute lung injury in rats.
【24h】

Long-acting local anesthetics attenuate FMLP-induced acute lung injury in rats.

机译:长效局麻药可减轻FMLP诱导的大鼠急性肺损伤。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Endothelin-1 (ET-1) is a mediator of lung diseases and a potent pulmonary vasoconstrictor. In addition to thromboxane A2, it participates in the formation of lung edema. Both lidocaine and mepivacaine attenuate the increase of pulmonary arterial pressure (PAP) and lung edema development. We examined the effects of procaine, bupivacaine, and ropivacaine on experimentally evoked PAP increase and ET-1 release. METHODS: PAP and lung weight were measured in isolated rat lungs during perfusion with Krebs-Henseleit hydroxyethyl starch buffer. Bupivacaine, ropivacaine, or procaine was added to the solution at concentrations of 10(-2)-10(-7) mg/kg. ET-1 levels were measured in the perfusate by enzyme-immunoassay, and thromboxane A2 levels were assayed by radioimmunoassay. N-formyl-L-leucine-methionyl-L-phenylalanine was used to activate human polymorphonuclear neutrophils. RESULTS: Bupivacaine, ropivacaine, and procaine significantly attenuated increases of PAP (P < 0.05) and resulted in a reduction of lung weight in these treatment groups compared with the sham group (P < 0.05). The long-acting anesthetics bupivacaine and ropivacaine (P < 0.05), but not procaine, reduced ET-1 levels, produced low inflammation rates, and did not affect lung structures at doses from 10(-3) to 10(-6) mg/kg. CONCLUSION: Bupivacaine and ropivacaine attenuated N-formyl-L-leucine-methionyl-L-phenylalanine-induced PAP, reduced lung edema, and diminished ET-1 release. Lidocaine and mepivacaine are more effective in reducing PAP and edema formation, but long-acting local anesthetics also inhibit ET-1 depletion and therefore have increased anti-inflammatory properties.
机译:背景:内皮素-1(ET-1)是肺部疾病的介质和有效的肺血管收缩剂。除血栓烷A2外,它还参与肺水肿的形成。利多卡因和甲哌卡因均可减弱肺动脉压(PAP)的升高和肺水肿的发展。我们检查了普鲁卡因,布比卡因和罗哌卡因对实验诱发的PAP升高和ET-1释放的影响。方法:使用Krebs-Henseleit羟乙基淀粉缓冲液对大鼠离体肺灌注过程中的PAP和肺重量进行测量。将布比卡因,罗哌卡因或普鲁卡因以10(-2)-10(-7)mg / kg的浓度添加到溶液中。通过酶联免疫法测定灌洗液中的ET-1水平,通过放射免疫法测定血栓烷A2水平。 N-甲酰基-L-亮氨酸-甲硫酰基-L-苯丙氨酸用于激活人多形核中性粒细胞。结果:与假手术组相比,这些治疗组中的布比卡因,罗哌卡因和普鲁卡因显着减弱了PAP的升高(P <0.05),并导致肺部重量减轻。长效麻醉药布比卡因和罗哌卡因(P <0.05),但不是普鲁卡因,可降低ET-1水平,降低发炎率并且在10(-3)至10(-6)mg剂量下不影响肺部结构/公斤。结论:布比卡因和罗哌卡因可减轻N-甲酰基-L-亮氨酸-甲硫酰基-L-苯丙氨酸诱导的PAP,减少肺水肿,并减少ET-1的释放。利多卡因和甲哌卡因在减少PAP和水肿形成方面更有效,但长效局麻药也抑制ET-1消耗,因此具有增强的抗炎特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号